Fusion of dendritic cells and tumor cells (FCs) constitutes a promising tool for generating an antitumor response because of their capacity to present tumor antigens and provide appropriate costimulatory signals. CD40-CD40L interaction has an important role in the maturation and survival of dendritic cells and provides critical help for T-cell priming. In this study, we sought to improve the effectiveness of FC vaccines in a murine model of B-cell lymphoma by engineering FCs to express CD40L by means of an adenovirus encoding CD40L (Adv-CD40L). Before transduction with Adv-CD40L, no CD40L expression was detected in FCs, DCs or tumor cells. The surface expression of CD40L in FC transduced with Adv-CD40L (FC-CD40L) ranged between 50 and 60%. FC-CD40L showed an enhanced expression of CD80, CD86, CD54 and MHC class II molecules and elicited a strong in vitro immune response in a syngeneic mixed lymphocyte reaction. Furthermore, FC-CD40L showed enhanced migration to secondary lymphoid organs. Splenocytes from mice treated with FC-CD40L had a dramatic increase in the production of IL-17, IL-6 and IFN-g, compared with controls. Treatment with the FC-CD40L vaccine induced regression of established tumors and increased survival. Our data demonstrate that FC transduced with Adv-CD40L enhances the antitumor effect of FC vaccines in a murine lymphoma model and this is associated with an increased Th17-type immune response.
Introduction
Dendritic cells (DCs) are the most professional antigenpresenting cells (APCs), and have a central role in the development of both innate and adaptive immune responses. 1, 2 DCs uptake antigens, process them and migrate to draining lymph nodes, where they efficiently prime CD4 + and CD8 + T-cell immunity. Several strategies to deliver tumor antigens (TAs) to DCs have been developed to generate a potent T-cell response against tumor cells. DCs pulsed with synthetic peptides derived from known TAs, tumor cell lysates or from apoptotic tumor cells can generate an antitumor response. 3, 4 In addition, DCs have been transfected with tumor-derived DNA or RNA, or transduced with recombinant viruses encoding known TAs or cytokine genes. [5] [6] [7] An alternative approach to the induction of antitumor immunity is the use of hybrid cells by fusing tumor cells with DCs. Fusion cells (FCs) may be generated by means of chemical agents (that is, PEG) or by electrofusion. The entire repertoire of TAs, including those known and those yet unidentified, is processed endogenously and presented by MHC class I and II pathways in the context of costimulatory signals. 8, 9 In addition, as the FC approach delivers not only TA epitopes but also the genes encoding those TAs, they continuously produce TA proteins for several days after fusion. 10 FCs function in a manner similar to APCs with the expression of costimulatory molecules and the ability to migrate to draining lymph nodes, in which they interact with CD4 + and CD8 + T cells and induce potent antitumor immunity. In addition, the use of several TAs may be simultaneously advantageous, as policlonal activation of T cells against different TAs could be a better approach to eradicate tumor cells. It is on that basis that this strategy has been studied in animal models for a number of cancers. [11] [12] [13] [14] [15] [16] The efficacy of this approach to promote systemic immunity in animal tumor models led to a vaccine clinical trial with FCs in patients with multiple myeloma. 17, 18 Although preliminary data are very encouraging, further refinements to improve the efficacy of this strategy are desirable, before it can be fully adopted in cancer patients.
Several studies have shown the importance of triggering CD40 molecules to enhance the efficiency of DCs as APCs. CD40 and its ligand CD40L have a critical role in the regulation of both humoral and cellular immune responses. CD40L enhances the DC expression of accessory molecules (that is, CD80, CD86, CD54 and CD58) that are crucial for T-cell activation. 19 Furthermore, engagement of CD40 by its ligand on DCs enhances the production of IL-12 20 and cell survival, 2 prolongs MHC/antigen complex presentation 21 and promotes antigen cross-priming. [20] [21] [22] [23] On the basis of these data, DCs have been genetically modified with recombinant adenoviruses to express CD40L (Adv-CD40L) to improve DC-based cancer vaccines. 24 With this approach, DCs showed an enhanced activation and costimulatory profile and promoted stronger T-cell cytolytic function, which eventually translated into an improved systemic antitumor effect in murine cancer models. 24 With this background, we investigated the effects of FCs genetically engineered to express the immunostimulatory gene CD40L in a mature B-cell lymphoma/ myeloma murine model. We show that, after transduction with an Adv-CD40L, FCs showed an increased expression of costimulatory molecules and induced a therapeutic systemic immune response in vivo in animals with preexisting tumor. Moreover, in our model, this approach compared favorably with the FC vaccine alone. Our results further support the use of FC vaccines for treating B-cell malignancies and additionally show refinements that may improve the efficacy of this vaccine in a clinical setting.
Results

Surface phenotype of FCs
DCs obtained before fusion expressed CD80, CD86, CD54, CD11c, CD40 and MHC class II. In contrast, the 4TOO tumor cell line only expressed CD54 and Syndecan-1 (CD138), a specific tumor marker and was negative for CD80, CD86, CD11c, CD40, CD40L and MHC class II (Figure 1 ). FCs were double positive for CD138 and CD11c, and expressed CD80, CD86, CD54, CD40 and MHC class II. The mean fusion efficiency was 30% (range 20-40%), determined on the basis of double staining for CD138 and MHC class II. None of the MIX cells showed double staining for CD138 and MHC class II.
Genetic modification of FCs with Adv-CD40L enhances their expression of costimulatory molecules
The expression of CD40 on FCs was first confirmed by flow cytometry. As shown in Figure 2a , FCs express moderate levels of CD40 (16±2%) but do not express CD40L. After transduction with Adv-CD40L, CD40L expression could be detected on a substantial proportion of FCs (55 ± 5%) but not on FCs transduced with Adv-GFP. In addition, the expression of CD40 in FC-CD40L significantly decreased 24 h after transduction, whereas it was maintained in FC-GFP. FC-CD40L cells were evaluated for the expression of costimulatory molecules by FACS analysis. As shown in Figure 2b , untransduced FCs expressed low levels of CD80, CD86 and CD54, and high levels of MHC class II. In contrast, FC-CD40L showed a significant increase in the expression of costimulatory molecules (CD80, CD86, CD54 and MHC class II) compared with FC-GFP and FCs mean fluorescence intensity; FC-GFP vs FC-CD40L, respectively: The FC-CD40L vaccine induces IFN-g and Th17-type cytokine secretion
Next, we assessed those cytokines that were secreted by immune cells from vaccinated mice. Splenocytes from mice vaccinated with FC-CD40L secreted significantly higher amounts of IL-2 and IFN-g, compared with mice vaccinated with FC-GFP (IL-2 3.3±0.3 ng ml -1 vs 1.7 ± 0.06 ng ml -1 , P ¼ 0.003; IFN-g 16.7 ± 2.9 vs 7.6±0.8 ng ml ; Po0.0001). Furthermore, IL-6 was preferentially secreted by FC-CD40L splenocytes (4.6 ± 0.5 ng ml -1 vs 0.7 ± 0.15 ng ml -1 ; Po0.0001), whereas there was a nonsignificant trend for a higher secretion of TGF-b by the FC-CD40L group (301±12.5 vs 256±17.3; P ¼ 0.5).
In vivo migration activity of FC-CD40L
To test whether FC-CD40L had a differential capacity to migrate to lymphoid tissues, we examined the percentage of CFSE-labeled FCs in lymph nodes, spleen, bone marrow and thymus 24 h after i.v. injection. Collectively, CFSE-positive FCs were observed mainly in the spleen 24 h after infusion ( Figure 5 ). FC-CD40L showed an enhanced migration to the spleen, compared with FC-GFP (2.8 ± 0.5% vs 1.6 ± 0.2%, respectively) or FCs (0.9±0.05%) (Po0.0001). In addition, FC-CD40L also migrated significantly better to the lymph nodes, as compared with FC-GFP or FCs (0.8±0.04% vs 0.35 ± 0.02% vs 0.3 ± 0.15%, respectively, Po0.0001). In contrast, migration of either untransduced FCs or transduced FCs to the thymus or bone marrow was negligible.
Treatment with FC-CD40L induces in vivo therapeutic antitumor immunity
We studied the capacity of the vaccine to stimulate systemic antitumor immunity in mice with preexisting tumors, a more clinically relevant setting. For these experiments, mice were first challenged i.v. with 2.5 Â 10 FC-CD40L had the best outcome, resulting in long-term survival of 40% of mice, whereas the administration of untransduced FCs or FC-GFP had no beneficial effect (40 vs 0%, P ¼ 0.012; Figure 6b ). No significant antitumor immunity was detected in mice treated with MIX cells, irrespective of whether or not they were transduced (10 vs 0%, P ¼ 0.43; Figure 6a ). In addition, live FC-CD40L-vaccinated mice received a second tumor challenge 3 months after the last vaccine. All mice rejected the tumor, suggesting the development of long-term immunity (data not shown).
Discussion
Several strategies to deliver tumor antigens to DCs have been developed to generate a potent CTL response against tumor cells in murine and human systems.
3,4,25
Fusions of DCs and tumor cells may have additional advantages over other DC-based vaccine methods, namely, the simultaneous presentation of a wide array of tumor antigens and costimulation. 26 This strategy has been proven to promote antitumor immunity in a number of solid tumor animal models. 12, 13, 16, [27] [28] [29] However, with regard to hematological tumors, very little information exists on the efficacy of this approach. Gong et al. tested the antitumor effect of FCs in a murine model of mature B-cell lymphoma/myeloma.
14 In this system, FC vaccines efficiently induced systemic immunity when they were administered to mice before the tumor. However, the same vaccine failed to induce long-term survival in tumor-bearing mice. To improve the efficacy of the FC vaccine in this scenario, IL-12 was administered systemically. However, a translation of this maneuver into clinical practice has limitations because of toxicities associated with systemic administration of IL-12.
30,31
Other studies have shown an improved efficacy of FC vaccines using DCs transduced with GM-CSF 32 or IL-12/ IL-18 genes. 13 Genetic manipulation of tumor cells or DCs with CD40L has consistently enhanced their capacity to induce sustained antitumor immune response. [33] [34] [35] Ligation of the CD40 molecule on DCs enhances their capacity as APCs, in Th1-type cytokine production (including IL-12) and cytotoxic T-cell stimulation. 20, 22, 23 In agreement with this, genetic modification of DCs with an adenovirus encoding the CD40L gene has been shown to significantly improve their antitumor effect in several murine cancer models. 24 
In our study, cell fusions were transduced with high efficiency, with more than 50% expressing the CD40L transgene, which resulted in phenotypic and functional changes. Thus, after transduction, the vast majority of FCs showed very high levels of MHC and costimulatory molecules, which suggests not only a direct effect of 
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Adv-CD40L on DCs but also a bystander effect of the expressed CD40L molecule on untransduced FCs. 36 In contrast to other studies in which DCs were transduced before the fusion process, we directly transduced FCs. This may have additional advantages in the case of CD40 + -B-cell malignancies, as CD40L may increase the expression of costimulatory molecules in the tumor cell partner of the fusion in addition to DCs. 33 In our study, FC-CD40L effectively stimulated syngeneic T cells, in line with CD40L-mediated T-helper activation. Remarkably, we show that FC-CD40L had an improved migration to spleen and lymph nodes compared with FCs or FC-GFP control. These data are in agreement with previous findings showing that DCs stimulated by CD40 had enhanced migration capability into secondary lymphoid organs and CTL stimulation. 37 The cytokine profile secretion of splenocytes from mice vaccinated with FC-CD40L resembles a Th1-type response, mediated by IL-2 and IFN-g. Surprisingly, we detected an increased production of IL-17, IL-6 and TGF-b cytokines in splenocytes of mice receiving the FC-CD40L vaccine, a pattern consistent with the generation of a Th17-polarized T-cell response. [38] [39] [40] Several studies have elucidated the role of cytokines involved in the generation of Th17 cells. In mice, IL-6 and TGF-b are critical cytokines involved in Th17 differentiation. 41 Interestingly, IL-6 production from DCs after CD40L stimulation has been recently shown as a major determinant for Th17 polarization. 42, 43 The fact that both IL-2 and IFN-g secretions have been detected mainly in cells from FC-CD40L-vaccinated mice suggests that Th1 cells could be involved in an antitumoral effect. However, as both human and murine Th17 cells produce IL-2 and IFN-g (that is, the so-called Th17-1), 44, 45 we cannot rule out Th17 cells as the main source of this cytokine. In fact, our data are consistent with recent findings showing that Th17 cells producing IFN-g are capable of mediating regression of established tumors in some murine models. 44, 46, 47 Collectively, our data suggest that, in our model, Th17-polarized cells mainly mediated tumor 45 Further studies with a selective depletion of effector cells will help to elucidate the exact role that these cells have in the observed antitumoral effect.
In summary, we have shown that hybrids of tumor cells and DCs transduced with CD40L induce systemic antitumor immunity, which, in contrast to untransduced fused cells, can eradicate established tumors. At present, FCs can be routinely generated for clinical administration into patients with cancer, and transduction of cells with Adv-CD40L under good manufacturing practice protocols has already been carried out for treating patients with hematological malignancies. 48 Our data may contribute to the generation of an improved FCbased vaccine that can be readily used in patients with hematological and other types of cancer.
Materials and methods
Mice
Female Balb/c mice (6 to 8 weeks old) were purchased from Charles River Breeding Laboratories (Barcelona, Spain) and housed at the Animal Maintenance Facility of Vall d'Hebron Hospital Research Institute (Barcelona, Spain). Mice were maintained in compliance with relevant laws and institutional care guidelines.
Cell lines
The murine 4TOO cell line, expressing MHC class I and CD138, as well as MHC class II negative (kindly provided by Dr M Khuel, NCI, Bethesda, MD, USA), was maintained in a complete medium (CM) consisting of RPMI 1640, supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin (all from PAA Laboratories GmbH, Pasching, Austria) and 50 mM 2-mercaptoethanol (Sigma-Aldrich, St Louis, MO, USA). Cells were grown in a suspension culture at 37 1C in 5% CO 2 .
Generation of DCs
DCs were generated from murine bone marrow cells as described by Lutz et al. 49 with minor modifications. Briefly, bone marrow was flushed from the long bones (femur, tibia and humerus) of Balb/c mice and depleted of red blood cells (RBC) by 5 min incubation with RBC lysis solution (Pharmlyse solution, BD Biosciencies Pharmingen, San Diego, CA, USA). Cells were washed and cultured in CM plus recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) (20 ng ml -1 ) (Peprotech, London, UK). On day 5 of culture, DCs were collected from the loosely adherent population and replated with fresh CM plus rmGM-CSF (20 ng ml -1 ). After 48 h, DCs were used for fusion.
Generation of FCs
Fusion of DCs and 4TOO tumor cells was carried out as described elsewhere with minor modifications.
14 Briefly, DCs were mixed with 4TOO at a 1:1 ratio, washed in RPMI-1640 and pelleted by centrifugation. The fusion ) at a 1:1 ratio, and were then used for experiments.
Immunophenotyping of DCs and FCs
DCs were collected after 7 days of culture, before fusion and the surface expression of the following markers was determined: MHC class II, CD80, CD86, CD11c, CD40, CD40L and CD54. To this end, 1 Â 10 6 cells were incubated in 50 ml of cold PBS supplemented with 1% bovine serum albumin (BSA; Sigma-Aldrich), 0.05% sodium azide (Sigma-Aldrich) and 10% rat serum FCs were characterized by dual staining. Cells were incubated with anti-Syndecan-1 (anti-CD138; BD Biosciences, Pharmingen), a specific marker for 4TOO cells, for 30 min at 4 1C, washed and then incubated with allophycocyanin (APC)-conjugated goat anti-mouse IgG (CALTAG Laboratories, Invitrogen, Spain). Thereafter, the cells were washed and incubated with FITCconjugated anti-mouse Ia/Ie (MHC class II) and PEconjugated anti-mouse CD80, CD86, CD11c, CD40, CD40L and CD54 (all from BD Biosciences Pharmingen). Appropriate isotype controls were used in all experiments. Analysis was performed with a FACscalibur flow cytometer (BD Biosciences) and data were analyzed with CellQuest 2.0 software (BD Biosciences). Fusion efficiency was described as the percentage of DCs coexpressing MHC class II and CD138 in concordance with others authors. 14 
Generation of recombinant adenoviruses
A recombinant adenovirus encoding the murine CD40L gene (Adv-CD40L) was generated as previously described. 33 The virus was expanded in 293 cells and purified by cesium chloride gradient ultracentrifugation. The purified virus was dialyzed extensively against PBS containing 10% glycerol, and aliquots were stored at À70 1C. Viral titers were determined by plaque assay on 293 cells. A control recombinant adenovirus expressing the green fluorescent protein (GFP) gene (Adv-GFP) was a gift from Dr M Brenner's laboratory (Center for Cell and Gene Therapy; Houston, TX, USA).
In vitro transduction of FCs with Adv-CD40L
FCs or MIX were transduced with Adv-CD40L (FC-CD40L or MIX-CD40L, respectively) or Adv-GFP (FC-GFP or MIX-GFP, respectively) as control. Briefly, FCs or MIX were plated at 1 Â 10 6 cells in RPMI-2% FCS medium. Adv-CD40L or Adv-GFP was added at a multiplicity of infection of 500, and incubated for 6 h in a humidified atmosphere containing 5% CO 2 at 37 1C. Thereafter, cells were resuspended in CM and, 24 h later, transduced cells were used for vaccine experiments. The expression of CD40L, CD40 and costimulatory molecules was assessed by flow cytometry using appropriate MAbs after gating on cells coexpressing MHC II and CD138. For this purpose, an aliquot of cells (1 Â 10 6 ) obtained 24-48 h after transduction was washed in PBS-1% BSA-0.05% sodium azide, and stained for 30 min on ice with a panel of PE-conjugated MAbs specific for murine CD80, CD86, CD54, CD40, CD40L, CD11c and Ia/Ie (MHC class II) (all from BD Biosciences Pharmingen). Appropriate isotype controls were used in all experiments. After incubation, cells were washed, fixed with 2% paraformaldehyde and analyzed using a FACscalibur flow cytometer (BD Biosciences) with the CellQuest 2.0 software (BD Biosciences).
Syngeneic mixed lymphocyte reactions
Groups of Balb/c mice (n ¼ 2 per group) were immunized twice, at weekly intervals, by i.v. injection of 1 Â 10 6 irradiated (30 Gy) FCs, FC-GFP or FC-CD40L cells. Mice from each vaccination group were killed 7 days after the second immunization, and their spleens were harvested. Splenic lymphocytes from mice of each representative group were pooled and cultured with irradiated (30 Gy) FCs, FC-GFP or FC-CD40L at a 1:1, 1:10 and 1:25 ratio for 5 days, in 96-well round-bottom tissue culture plates. On day 5, [ 3 H]-thymidine (1 mCi per well)(Amersham GE Healthcare, Amersham, UK) was added during the last 18 h of the culture. All determinations were carried out in triplicate, and thymidine incorporation was determined with a b-counter (Beckman Coulter LS 6500, Beckman Instruments Inc., CA, USA).
In vivo migration assay of FCs
Immediately before injection, FCs or transduced FCs (FC-GFP or FC-CD40L) were labeled with 5 mM CFSE (Molecular Probes Europe BV, The Netherlands) in PBS at 37 1C for 15 min and washed twice. Mice were injected i.v. with 5 Â 10 6 CFSE-labeled FCs. After 24 h, lymph node, spleen, bone marrow and thymus samples were harvested, and the percentage of FCs, FC-GFP and FC-CD40L CFSE + cells was determined by FACS analysis.
Quantification of cytokines
The concentrations of IL-2, IL-6, IL-17 and IFN-g (FlowCytomix), as well as TGF-b1 (ELISA), all from Bender MedSystems (Vienna, Austria), were measured in supernatants obtained from the syngeneic mixed lymphocyte reaction cultures, according to the manufacturer's instructions. 
Statistical analysis
Results are expressed as mean ± s.d. Paired Student's t-test was used for comparisons. Survival analysis was performed using GraphPad Prism 5 software (San Diego, CA, USA), and statistical differences in survival were calculated by the log-rank test. A Po0.05 was considered to be statistically significant.
